COPD and noninvasive ventilation

Reducing hospital readmissions, improving quality of life

For more than three decades Philips Respironics has been developing meaningful innovations and providing service and support aimed at maximizing your clinical success. We continue that commitment in support of patients and providers in an effort to help reduce potential hospital readmissions for acute exacerbations of COPD.

Consider the following:

- In 2012, over one million COPD patients were admitted to US hospitals for acute exacerbation.\(^1\)
- Hospital readmissions for COPD within 30 days occur in 23% of cases.\(^2\)
- Many of these readmissions may be preventable.\(^3\)
- The estimated cost of these readmissions to the US healthcare system is over $49 billion.\(^3\)
- Hospitalizations are among the most expensive forms of healthcare, and inpatient stays increase the risk of acquiring healthcare-associated infections.\(^4\)

There is strong evidence that supports noninvasive ventilation (NIV) as an effective therapy option for most COPD patients hospitalized with acute exacerbations.\(^5\)

NIV has shown to be the most effective treatment option for reducing CO\(_2\) in hypercapnic COPD patients. When initiated early, this can help reduce hospital admission rates, length of stay, and the cost of healthcare while maintaining or improving quality of life.\(^5\)

Several clinical studies on NIV for hypercapnic COPD show improved blood gases and lower hospitalization rates compared to patients not treated with NIV at home.\(^6,7\)

NIV therapy solutions

BiPAP S/T
Basic ventilation with backup rate in a noninvasive ventilator that is compact, lightweight and simple to operate. BiPAP S/T incorporates proven BiPAP technology, Digital Auto-Trak sensitivity, adjustable rise time, integrated alarms, and Encore and DirectView patient management systems.

BiPAP AVAPS
Ideal for treating patients with COPD and other diseases that cause hypoventilation. AVAPS provides a targeted tidal volume for each breath and has been shown to reduce elevated CO₂ levels. It offers pressure support up to 30 cm H₂O and includes Encore and DirectView patient management systems.

Ordering information

<table>
<thead>
<tr>
<th>Item</th>
<th>Part number</th>
</tr>
</thead>
<tbody>
<tr>
<td>BiPAP S/T</td>
<td>DS1060S</td>
</tr>
<tr>
<td>BiPAP S/T, with humidifier</td>
<td>DS1060HS</td>
</tr>
<tr>
<td>BiPAP S/T, with Heated Tube humidifier</td>
<td>DS1060TS</td>
</tr>
<tr>
<td>BiPAP AVAPS</td>
<td>DS1160S</td>
</tr>
<tr>
<td>BiPAP AVAPS, with humidifier</td>
<td>DS1160HS</td>
</tr>
<tr>
<td>BiPAP AVAPS, with Heated Tube humidifier</td>
<td>DS1160TS</td>
</tr>
<tr>
<td>Trilogy100</td>
<td>1054260</td>
</tr>
</tbody>
</table>

Philips Respironics NIV advanced technologies provide comfort and synchrony for patients suffering with respiratory insufficiency, including COPD.

Digital Auto-Trak enables exceptional patient/ventilator synchrony by automatically adjusting variable trigger and cycle thresholds—all while recognizing and compensating for leak.

AVAPS (Average Volume Assured Pressure Support) automatically adapts to disease progression and changing patient needs while maintaining a target tidal volume, and has been shown to reduce elevated CO₂ levels.

AVAPS-AE offers additional automatic adjustment of EPAP (Expiratory Positive Airway Pressure) and a backup breath rate to meet the needs of the most challenging patients, including those needing longer expiratory times to reduce the effects of flow limitation and air trapping.

Contact your Philips Respironics account representative for more information

© 2013 Koninklijke Philips N.V. All rights are reserved.

Philips Healthcare reserves the right to make changes in specifications and/or to discontinue any product at any time without notice or obligation and will not be liable for any consequences resulting from the use of this publication.

CAUTION: US federal law restricts these devices to sale by or on the order of a physician.

Geyer JAH 10/09/13 MCI 4105869 PN 1113130